New York, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)CANCER RESEARCH FUND OF THE DAMON RUNYON-WALTER WINCHELL FOUNDATION, founded in 1947, is a mid-sized nonprofit in the Health Care sector that reported $54.7M in total revenue in fiscal year 2024. Revenue surged 180% from the prior year, signaling strong growth momentum. The organization ran a surplus of $29.6M, a strong 54% operating margin.
TO ACCELERATE BREAKTHROUGHS BY PROVIDING TODAY'S BEST YOUNG SCIENTISTS WITH FUNDING TO PURSUE INNOVATIVE CANCER RESEARCH. THE FOUNDATION'S GOALS ARE TO IDENTIFY AND FUND THE BEST AND BRIGHTEST EARLY-CAREER SCIENTISTS IN CANCER RESEARCH; ENABLE THEM TO TAKE RISKS ON BOLD NEW IDEAS; AND ACCELERATE THE TRANSLATION OF SCIENTIFIC DISCOVERIES INTO NEW WAYS TO PREVENT OR CURE ALL FORMS OF CANCER. ITS INTERNATIONALLY RECOGNIZED AND HIGHLY COMPETITIVE GRANT PROGRAMS ARE DESIGNED TO ACHIEVE THESE GOALS.
FELLOWSHIP AWARDS: SUPPORTS THE TRAINING OF THE BRIGHTEST POSTDOCTORAL SCIENTISTS AS THEY EMBARK UPON THEIR RESEARCH CAREERS. THIS FUNDING ENABLES THEM TO BE TRAINED BY ESTABLISHED INVESTIGATORS IN...
FELLOWSHIP AWARDS: SUPPORTS THE TRAINING OF THE BRIGHTEST POSTDOCTORAL SCIENTISTS AS THEY EMBARK UPON THEIR RESEARCH CAREERS. THIS FUNDING ENABLES THEM TO BE TRAINED BY ESTABLISHED INVESTIGATORS IN LEADING RESEARCH LABORATORIES ACROSS THE COUNTRY, WHILE INDEPENDENTLY CONDUCTING LEADING-EDGE SCIENCE THAT WILL BRING NEW UNDERSTANDING AND CURES FOR CANCER.
CLINICAL INVESTIGATOR AWARDS: SUPPORTS EARLY CAREER PHYSICIAN-SCIENTISTS CONDUCTING PATIENT-ORIENTED RESEARCH. THE GOAL OF THIS PROGRAM IS TO INCREASE THE NUMBER OF PHYSICIANS CAPABLE OF MOVING...
CLINICAL INVESTIGATOR AWARDS: SUPPORTS EARLY CAREER PHYSICIAN-SCIENTISTS CONDUCTING PATIENT-ORIENTED RESEARCH. THE GOAL OF THIS PROGRAM IS TO INCREASE THE NUMBER OF PHYSICIANS CAPABLE OF MOVING SEAMLESSLY BETWEEN THE LABORATORY AND THE PATIENT'S BEDSIDE IN SEARCH OF BREAKTHROUGH TREATMENTS.
RACHLEFF INNOVATION AWARDS: SUPPORTS THE NEXT GENERATION OF EXCEPTIONALLY CREATIVE THINKERS WITH "HIGH RISK/HIGH REWARD" IDEAS THAT HAVE THE POTENTIAL TO SIGNIFICANTLY IMPACT OUR UNDERSTANDING OF...
RACHLEFF INNOVATION AWARDS: SUPPORTS THE NEXT GENERATION OF EXCEPTIONALLY CREATIVE THINKERS WITH "HIGH RISK/HIGH REWARD" IDEAS THAT HAVE THE POTENTIAL TO SIGNIFICANTLY IMPACT OUR UNDERSTANDING OF AND/OR APPROACHES TO THE PREVENTION, DIAGNOSIS OR TREATMENT OF CANCER, BUT LACK SUFFICIENT PRELIMINARY DATA TO OBTAIN TRADITIONAL FUNDING.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $54,683,607 | $19,559,693 | +1.8% |
| Expenses | $25,059,618 | $25,408,684 | 0.0% |
| Net Income | $29,623,989 | $-5,848,991 | -6.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ANDREW S RACHLEFF | CHAIR (AS OF 10/15/24) | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| DAVID G MARSHALL | VICE CHAIR, INVESTMENTS & TREASURER (THRU 6/10/25) | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| DAVID M BEIRNE | VICE CHAIR, BOARD DEVELOPMENT | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| DEBORAH J COLEMAN | SECRETARY (AS OF 6/10/25) | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| LAURENCE W COHEN | TREASURER (AS OF 10/15/24) | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| MICHAEL L GORDON | VICE CHAIR, BOARD DEVELOPMENT (THRU 10/15/24) | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| SANFORD W MORHOUSE ESQ | VICE CHAIR, AUDIT & SECRETARY (THRU 6/10/25) | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| WILLIAM G KAELIN JR MD | VICE CHAIR, SCIENTIFIC PROGRAMS | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| ADAM R SCHWARTZ | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| AMOOLYA SINGH PHD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| BUCK FRENCH | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| CARLOS L ARTEAGA MD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| CYNTHIA SULZBERGER | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| DAVID A GORDON PHD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| ELAINE V FUCHS PHD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| ERICA EVANS GIOFFRE | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| GABRIELLE LAYTON PHD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| GARY E ERLBAUM | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| GERALD M MARSHALL | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| JAMES WELLS PHD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| JOHN H MYERS | DIRECTOR (THRU 10/15/24) | 1.0 |
Director
|
$0 | $0 | $0 |
| JOSEPH PEARLBERG MD PHD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| JUDY SWANSON | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| KAREN D SEITZ | DIRECTOR (THRU 10/15/24) | 1.0 |
Director
|
$0 | $0 | $0 |
| LEVI A GARRAWAY MD PHD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| LORI J PIERCE MD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| MELISSA L COHN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| MICHAEL V SEIDEN MD PHD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| MORANA JOVAN-EMBIRICOS PHD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| NANCY SIMONIAN MD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| NOAH KNAUF | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| PETER VAN CAMP | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| RICHARD B GAYNOR MD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| RICHARD HOFFMAN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| RICHARD J O'REILLY MD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| RICHARD W MEIER | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| ROBYN COLES | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| SCOTT GREENSTEIN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| STEVEN A KANDARIAN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| STEVEN J BURAKOFF MD | DIRECTOR (THRU 10/15/24) | 1.0 |
Director
|
$0 | $0 | $0 |
| TODD R GOLUB MD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| YUNG S LIE PHD | PRESIDENT & CEO | 40.0 |
Officer
|
$592,380 | $59,913 | $652,293 |
| CLARE CAHILL | CHIEF ADMINISTRATIVE OFFICER | 40.0 |
Highest
|
$253,185 | $36,955 | $290,140 |
| ELYSE HOFFMANN | SENIOR DIRECTOR OF STRATEGIC PARTNERSHIP | 40.0 |
Highest
|
$199,837 | $39,199 | $239,036 |
| KIMBERLY KUBERT | DIRECTOR OF SPECIAL EVENTS | 40.0 |
Highest
|
$211,585 | $35,757 | $247,342 |
| MEGAN ALLEN PHD | SCIENTIFIC DIRECTOR | 40.0 |
Highest
|
$143,407 | $24,343 | $167,750 |
| MEGHAN MCCURDY | DIRECTOR OF COMMUNICATIONS & MARKETING | 40.0 |
Highest
|
$157,037 | $43,527 | $200,564 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $54,683,607 | $25,059,618 | $170,380,475 | $29,623,989 |
| 2024 | $19,559,693 | $25,408,684 | $160,511,709 | $-5,848,991 |
| 2023 | $15,715,675 | $21,219,216 | $147,680,687 | $-5,503,541 |
| 2022 | $14,385,319 | $21,596,927 | $143,543,813 | $-7,211,608 |
| 2021 | $20,562,891 | $20,352,745 | $175,580,654 | $210,146 |
| 2020 | $54,248,600 | $23,330,168 | $148,107,071 | $30,918,432 |
| 2019 | $21,005,283 | $25,301,097 | $150,535,887 | $-4,295,814 |
| 2018 | $21,568,069 | $21,204,617 | $148,707,992 | $363,452 |
Compare CANCER RESEARCH FUND OF THE DAMON RUNYON-WALTER WINCHELL FOUNDATION with other nonprofits in New York and across the country.